Regeneron Pharmaceuticals (REGN)
(Real Time Quote from BATS)
$1,042.25 USD
-49.73 (-4.55%)
Updated Sep 24, 2024 10:58 AM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
REGN 1,042.25 -49.73(-4.55%)
Will REGN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for REGN
Regeneron, SNY's Dupixent Get CHMP Recommendation for Label Expansion
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Other News for REGN
Video: Nasdaq 100 Movers: REGN, PDD
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar (update)